Can a targeted pill shrink a rare, Treatment-Resistant stomach cancer?
NCT ID NCT06640361
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This phase 3 trial is testing whether the experimental drug olverembatinib can slow or stop tumor growth in people with a rare form of gastrointestinal stromal tumor (GIST) that lacks a key enzyme called SDH. The study enrolls adults whose cancer has progressed after at least one prior treatment. Participants take olverembatinib by mouth every other day, and researchers will track how long the cancer stays under control and what side effects occur.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a drug called olverembatinib, taken by mouth every other day
- What this could lead to
- If successful, this could provide a new treatment option for people with a rare, hard-to-treat form of stomach cancer that has stopped responding to other therapies.
- What could go wrong
- This is a small, single-arm trial with no comparison group, so results may be less definitive. Side effects are possible, and the drug may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GIST are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Massive GIST registry aims to unlock secrets of rare cancer
- New hope for stomach cancer patients Who've tried everything?
- New hope for GIST: experimental combo targets hard-to-treat tumors
- New study seeks best way to remove stomach tumors without major surgery
- Hunt for hidden cancer genes: families needed to unlock hereditary secrets
- New combo therapy targets hard-to-treat GIST tumors